147458 - an overview of vaccine development.pdf (1.04 MB)
An overview of vaccine development for COVID-19
journal contribution
posted on 2023-05-21, 03:40 authored by Shahcheraghi, SH, Ayatollahi, J, Aljabali, AAA, Madhur ShastriMadhur Shastri, Shukla, SD, Chellappan, DK, Jha, NK, Anand, K, Katari, NK, Mehta, M, Satija, S, Dureja, H, Mishra, V, Almutary, AG, Alnuqaydan, AM, Charbe, N, Prasher, P, Gupta, G, Dua, K, Lotfi, M, Bakshi, HA, Tambuwala, MMThe COVID-19 pandemic continues to endanger world health and the economy. The causative SARS-CoV-2 coronavirus has a unique replication system. The end point of the COVID-19 pandemic is either herd immunity or widespread availability of an effective vaccine. Multiple candidate vaccines - peptide, virus-like particle, viral vectors (replicating and nonreplicating), nucleic acids (DNA or RNA), live attenuated virus, recombinant designed proteins and inactivated virus - are presently under various stages of expansion, and a small number of vaccine candidates have progressed into clinical phases. At the time of writing, three major pharmaceutical companies, namely Pfizer and Moderna, have their vaccines under mass production and administered to the public. This review aims to investigate the most critical vaccines developed for COVID-19 to date.
History
Publication title
Therapeutic DeliveryVolume
12Pagination
235-244ISSN
2041-5990Department/School
School of Pharmacy and PharmacologyPublisher
Future Science Ltd.Place of publication
United KingdomRights statement
Copyright 2021 Murtaza Tambuwala. This work is licensed under the Creative Commons Attribution 4.0 License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/Repository Status
- Open